Chronic Heart Failure

Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction

The EMPEROR-Preserved trial evaluated the efficacy of empagliflozin, an SGLT2 inhibitor, in patients with chronic heart failure with preserved ejection fraction (HFpEF). This international, multicenter study included 5,998 participants and was conducted across 622 centers in 23 countries. Patients were randomized to receive either empagliflozin (10 mg daily) or a placebo, alongside standard care, over a median follow-up period of 26 months.

Key findings from the trial include a 21% reduction in the combined risk of cardiovascular death or hospitalization for heart failure among those treated with empagliflozin compared to placebo. The reduction in total heart failure hospitalizations was even more pronounced at 27%. These benefits were observed regardless of the presence of diabetes. Empagliflozin also slowed the decline in renal function compared to the placebo group, further highlighting its potential therapeutic advantages in HFpEF management​

    Related Conference of Chronic Heart Failure

    October 20-21, 2025

    39th World Congress on Heart Diseases

    Frankfurt, Germany
    November 13-14, 2025

    6th Global Summit on Heart Congress

    Paris, France
    November 19-20, 2025

    7th World Heart Congress

    Tokyo, Japan
    November 24-25, 2025

    36th Annual Cardiologists Conference

    Barcelona, Spain
    November 27-28, 2025

    32nd World Heartcare Summit

    Paris, France
    January 12-13, 2026

    12th International Heart Conference

    Dubai, UAE
    March 18-19, 2026

    15th World Heart Congress

    Paris, France
    March 23-24, 2026

    41st World Cardiology Conference

    London, UK
    April 08-29, 2026

    9th Annual Heart Rhythm Conference

    Vienna, Austria
    April 13-14, 2026

    9th World Heart and Brain Conference

    Tokyo, Japan
    May 14-15, 2026

    5th International Conference on Cardiology

    Rome, Italy
    May 21-22, 2026

    15th World Congress on Cardiology

    London, UK
    July 29-30, 2026

    30th World Cardiology Conference

    Paris, France

    Chronic Heart Failure Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in